看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
4 r* i* ~( R" T5 Y
+ g, d3 c- |& z
: l. j( A2 H% q6 B. b7 S4 B0 WCurrently available feasibility data for possible combination strategies.
V0 y0 s9 L6 ~, t( t2 e" _————————————————————————————————; h5 L9 X3 Y6 ~8 B* A3 N# B! b
Combination Feasibility according to preliminary data
, |" Z% J3 A% _5 }4 I" q——————————————————————————————————! {! m2 M. i; G
Bevacizumab + sorafenib Yes, reduced dose
& N' N0 w- Y" g$ r9 M1 LBevacizumab + sunitinib† No
2 B2 z9 e2 Q$ e/ Z, G S# F6 l+ jBevacizumab + temsirolimus Yes / M Z4 z% A, g) ]; y, i9 e* P: a
Bevacizumab + everolimus Yes
) \. R+ r& @0 J; vSorafenib + sunitinib ?
: S. {' ~6 {# E) ?* J4 r. ZSorafenib + temsirolimus Yes, reduced dose 1 R& c5 h3 Y4 x5 L8 q
Sorafenib + everolimus Yes, reduced dose ; ~, r, J4 ~: U
Sunitinib + temsirolimus† No + Y; n$ O' ^, _
Sunitinib + everolimus ?
8 U# V+ s3 W. [+ k* z( |Temsirolimus + everolimus ?
" _- e+ ^7 Y: K+ v( K6 Q! }————————————————————- |# D5 c% q/ W8 c2 Q
†Led to US FDA warning.
7 M" Q+ F1 Y8 B! l7 O% M# i9 ]?: As yet unattempted combination.9 t! e6 V+ A, D
|